title: mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer.
abstract: Breast cancer susceptibility gene 1 (BRCA1) has a central role in chemotherapy-induced DNA damage response. The protein inhibitor of activated STAT (PIAS) family of proteins, PIAS1 and PIAS4, are also necessary for adequate DNA damage repair. To further understand the role of BRCA1 in DNA repair, we examined the mRNA expression of these genes in 133 advanced (stage III-IV) gastric cancer patients using quantitative reverse transcription polymerase chain reaction. All P values were two-sided. The median overall survival was 12.5 months (95% confidence interval [CI] = 9.8 to 13.4 months). Among 59 patients receiving second-line docetaxel, the median overall survival was 25.8 months (95% CI = 9.2 to 42.4 months) for patients with high BRCA1 expression, 19.1 months (95% CI = 3.4 to 34.8 months) for those with intermediate expression, and 9.5 months (95% CI = 8.7 to 10.2 months) for those with low expression (P = .0062). The risk of mortality was higher in patients with low BRCA1 levels compared with high BRCA1 levels (hazard ratio of death = 2.49, 95% CI = 1.03 to 5.97, P = .037). Survival in patients receiving second-line docetaxel-based chemotherapy showed a similar trend with PIAS1 and PIAS4 mRNA expression levels, although the associations for PIAS4 were not statistically significant.
authors.affiliation: Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, 321 Zhongshan Rd., Nanjing, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Wei
authors.forename: Carlota
authors.initials: C
authors.lastname: Costa
authors.forename: Yitao
authors.initials: Y
authors.lastname: Ding
authors.forename: Zhengyun
authors.initials: Z
authors.lastname: Zou
authors.forename: Lixia
authors.initials: L
authors.lastname: Yu
authors.forename: Jose Javier
authors.initials: JJ
authors.lastname: Sanchez
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Qian
authors.forename: Hong
authors.initials: H
authors.lastname: Chen
authors.forename: Ana
authors.initials: A
authors.lastname: Gimenez-Capitan
authors.forename: Fanqing
authors.initials: F
authors.lastname: Meng
authors.forename: Teresa
authors.initials: T
authors.lastname: Moran
authors.forename: Susana
authors.initials: S
authors.lastname: Benlloch
authors.forename: Miquel
authors.initials: M
authors.lastname: Taron
authors.forename: Rafael
authors.initials: R
authors.lastname: Rosell
authors.forename: Baorui
authors.initials: B
authors.lastname: Liu
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality; D002288:Adenocarcinoma, Mucinous / Q000378:metabolism / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019313:BRCA1 Protein / Q000235:genetics / Q000378:metabolism*; D002277:Carcinoma / Q000378:metabolism* / Q000401:mortality*; D018196:Carcinoma, Adenosquamous / Q000378:metabolism / Q000401:mortality; D018279:Carcinoma, Signet Ring Cell / Q000378:metabolism / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D000077143:Docetaxel; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016017:Odds Ratio; D000075223:Poly-ADP-Ribose Binding Proteins; D050828:Protein Inhibitors of Activated STAT / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D012189:Retrospective Studies; D025841:Small Ubiquitin-Related Modifier Proteins / Q000235:genetics / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D019313:BRCA1 Protein; C106529:PIAS1 protein, human; C485891:PIAS4 protein, human; D000075223:Poly-ADP-Ribose Binding Proteins; D050828:Protein Inhibitors of Activated STAT; D012333:RNA, Messenger; D025841:Small Ubiquitin-Related Modifier Proteins; D043823:Taxoids; D000077143:Docetaxel